|
KAI Pharmaceuticals Announces Phase 1 Results of KAI-4169 for the Treatment of SHPT |
July 20, 2010
|
|
Read more...
|
|
|
KAI Reports Positive Preclinical Results in Pain Therapeutic Program Targeting Gamma PKC Pathway |
October 20, 2009
|
|
Read more...
|
|
|
KAI Acquires Patents, Broadening KAI’s IP Estate Covering Peptide-Based Therapies |
June 30, 2009
|
|
Read more...
|
|
|
KAI Initiates Third Phase 2a Study to Develop KAI-1678 for the Treatment of Neuropathic Pain |
April 8, 2009
|
|
Read more...
|
|
|
KAI Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain |
March 31, 2009
|
|
Read more...
|
|
|
KAI Pharmaceuticals Initiates Phase 2b Clinical Study of KAI-9803 in Heart Attack Patients |
December 17, 2008
|
|
Read more...
|
|
|
KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain |
December 10, 2008
|
|
Read more...
|
|
|
KAI Reports Positive Preclinical Results for KAI-1678 |
November 19, 2008
|
|
Read more...
|
|
|
KAI Pharmaceuticals Advances Third Product Candidate into Clinical Studies |
May 20, 2008
|
|
Read more...
|
|
|
Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance |
May 13, 2008
|
|
Read more...
|
| |
|
|
